Lactate dehydrogenase is the Achilles’ heel of Lyme disease bacterium Borreliella burgdorferi
mBio · 2025
DOI: 10.1128/mbio.03728-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2025. Verfasst von Ching Wooen Sze und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Craniofacial Molecular Biology, Virginia Commonwealth University, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Borrelia burgdorferi, Lyme Disease, L-Lactate Dehydrogenase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
As a zoonotic pathogen, the Lyme disease bacterium Borreliella burgdorferi has evolved unique metabolic pathways, some of which are specific and essential for its survival and thus present as ideal targets for developing new therapeutics. B. burgdorferi dispenses with the use of thiamin as a cofactor and relies on lactate dehydrogenase (BbLDH) to convert pyruvate to lactate for balancing NADH/NAD + ratios. This report first demonstrates that BbLDH is a canonical LDH with some unique biochemical and structural features. A loss-of-function study then reveals that BbLDH is essential for B. burgdorferi survival and infectivity, highlighting its therapeutic potential. Drug screening identifies four previously unknown LDH inhibitors with minimal cytotoxicity, two of which inhibit B. burgdorferi growth. This study provides mechanistic insights into the function of BbLDH in the pathophysiology of B. burgdorferi and lays the groundwork for developing genus-specific metabolic inhibitors against B. burgdorferi and potentially other tick-borne pathogens as well. IMPORTANCE Lyme disease (LD) is the most commonly reported tick-borne illness in the U.S. and Europe, and its geographic distribution is continuously expanding worldwide. Though early LD can be treated with antibiotics, chronic LD is recalcitrant to antibiotic treatments and thus requires multiple courses of antibiotic therapy. Currently, there are no human vaccines nor prophylactic antibiotics to prevent LD. As the causative agent of LD, Borreliella burgdorferi has evolved unique metabolic pathways, some of which are specific and essential for its survival and thus present as ideal targets for developing new therapeutics. By using an approach of genetics, biochemistry, structural biology, drug screening, and animal models, this report provides evidence that lactate dehydrogenase can be a potential target for developing genus-specific metabolic inhibitors against B. burgdorferi and potentially other tick-borne pathogens as well.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Craniofacial Molecular Biology, Virginia Commonwealth University, Richmond, Virginia, USA.
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York, USA.
- Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, Virginia, USA.
ORCID-Profile: Michael J Lynch, Brian R Crane, Chunhao Li
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
Zitieren
APA
Sze, C. W., Lynch, M. J., Zhang, K., Neau, D. B., Ealick, S. E., Crane, B. R., & Li, C. (2025). Lactate dehydrogenase is the Achilles’ heel of Lyme disease bacterium Borreliella burgdorferi. mBio. https://doi.org/10.1128/mbio.03728-24
Vancouver
Sze CW, Lynch MJ, Zhang K, Neau DB, Ealick SE, Crane BR, et al. Lactate dehydrogenase is the Achilles’ heel of Lyme disease bacterium Borreliella burgdorferi. mBio. 2025. doi:10.1128/mbio.03728-24
BibTeX
@article{Sze2025,
author = {Sze, Ching Wooen and Lynch, Michael J and Zhang, Kai and Neau, David B and Ealick, Steven E and Crane, Brian R and Li, Chunhao},
title = {Lactate dehydrogenase is the Achilles’ heel of Lyme disease bacterium Borreliella burgdorferi},
journal = {mBio},
year = {2025},
doi = {10.1128/mbio.03728-24}
}
EUVIMED